Developing Models to Predict <i>BRAF</i>V600E and <i>RAS</i> Mutational Status in Papillary Thyroid Carcinoma Using Clinicopathological Features and pERK1/2 Immunohistochemistry Expression
The Cancer Genome Atlas (TCGA) has classified papillary thyroid carcinoma (PTC) into indolent RAS-like and aggressive BRAF-like based on its distinct driver gene mutations. This retrospective study aimed to assess clinicopathology and pERK1/2 expression variations between BRAF-like and RAS-like PTCs...
Main Authors: | Agnes Stephanie Harahap, Imam Subekti, Sonar Soni Panigoro, Asmarinah, Lisnawati, Retno Asti Werdhani, Hasrayati Agustina, Dina Khoirunnisa, Mutiah Mutmainnah, Fajar Lamhot Gultom, Abdillah Hasbi Assadyk, Maria Francisca Ham |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-10-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/11/10/2803 |
Similar Items
-
Indeterminate Thyroid Nodules: From Cytology to Molecular Testing
by: Paola Vignali, et al.
Published: (2023-09-01) -
Association of DNA Promoter Methylation and <i>BRAF</i> Mutation in Thyroid Cancer
by: Farzana Jasmine, et al.
Published: (2023-03-01) -
Effect of Having Concurrent Mutations on the Degree of Aggressiveness in Patients with Thyroid Cancer Positive for <i>TERT</i> Promoter Mutations
by: Sama Alohali, et al.
Published: (2023-01-01) -
<i>BRAF</i> Inhibitors in <i>BRAF-Mutated</i> Colorectal Cancer: A Systematic Review
by: Wajeeha Aiman, et al.
Published: (2023-12-01) -
PKM2 Expression as Biomarker for Resistance to Oxaliplatin-Based Chemotherapy in Colorectal Cancer
by: Maria Sfakianaki, et al.
Published: (2020-07-01)